Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
Celsis International
Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
Recent Comments